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Purpose: To identify the causative paired box 6 (PAX6) mutation in a family with autosomal dominant aniridia.
Methods: A family with autosomal dominant aniridia with three affected individuals in two generations was investigated
for the causative PAX6 mutation by single strand conformation polymorphism (SSCP) followed by sequencing of genomic
DNA from peripheral blood.
Results: A novel PAX6 mutation in the donor splice site of intron 12 was identified in all three affected individuals from
the family. The automated splice site analysis web interface indicated a disturbance of splicing and it was predicted that
this mutation could lead to an elimination of the normal stop codon and an abnormal 3′ elongation of the mRNA.
Conclusions: We report a novel PAX6 mutation in autosomal dominant aniridia that presumably affects splicing. The
presence of chorioretinal degeneration in one of the affected individual raises the possibility that run-on mutations are
associated with chorioretinal involvement in aniridia.
Aniridia  (OMIM  106210)  is  a  panocular  disorder
characterized by variable degrees of deficiency of the iris
tissue. In 70% cases it presents as a familial disorder with
autosomal dominant inheritance. The paired box 6 (PAX6)
gene is the only gene in which causative mutations have been
identified [1,2]. Mutations leading to complete absence of the
PAX6 protein are responsible for aniridia phenotype whereas
milder mutations with protein production are associated with
other ocular presentations like corectopia, Reiger anomaly,
cataract,  glaucoma,  etc  [3-5].  Until  date,  718  sequence
variants of PAX6 and 321 pathogenic mutations have been
recorded [6]. In the present paper we report the finding of a
novel PAX6 mutation in an Indian family with aniridia. We
also attempt to correlate the rare occurrence of chorioretinal
degeneration in one of the affected individual with the type of
mutation.
METHODS
Case description: A family with an affected father and his two
affected  sons  had  attended  the  genetics  department  of  a
tertiary care hospital in North India. The family hailed from
the local population and had no other similarly affected family
member in the previous generations.
The proband was the elder son, who was 21 years at the
time  of  workup.  He  had  complete  absence  of  iris  tissue,
microcornea, anterior polar cataract, glaucoma, and immature
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cortical cataract in both eyes. In addition he had chorioretinal
degeneration and multiple vitreous opacities in the right eye
and retinal pigment epithelium depigmentation changes in the
left eye. However his vision was relatively well conserved and
he could carry out his daily chores with the aid of corrective
glasses. He had undergone corrective surgery for glaucoma in
both eyes 4 years ago. His intra-ocular pressure which was
43 mm-45 mm in both eyes was reduced to 14 mm after the
surgery.
His younger brother who was 18 years old was legally
blind since the age of 8 years. He also had complete absence
of iris tissue in both eyes. In addition, he also had bilateral
microcornea and opacification of both corneas more on the
left  side.  He  had  glaucoma  in  the  right  eye  (Intra-ocular
pressure 28 mmHg) and cataract in the left eye. The left eye
was  diagnosed  as  having  developed  phthisis  bulbi.  These
asymmetric eye findings in this patient could be attributed to
previous injury to the left eye at the age of 14.
The father was 45 years old and was legally blind. He had
progressive visual loss since age of 25 years. On examination,
he also had absence of iris tissue in both eyes. He had bilateral
corneal opacities and marked thinning of the cornea. He also
had optic nerve atrophy in bilateral eyes, probably due to long
standing  glaucoma  but  no  prior  medical  records  were
available. The pedigree is depicted in Figure 1.
Mutation  analysis:  Mutation  analysis  was  done  at  the
Department  of  Research  and  Development,  Faculty  of
Medicine,  Siriraj  Hospital  Mahidol  University,  Bangkok.
Mutation screening in 14 exons of PAX6 was performed using
single strand conformation polymorphism (SSCP) followed
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1306by direct DNA sequencing. The primers used are as mentioned
by Atchaneeyasakul et al. [7] and shown in Table 1.
RESULTS
A heterozygous nucleotide substitution at the splice donor site
of intron 12 (IVS12+2T>C) of PAX6 was identified in the
DNA samples from all three affected individuals. Screening
for IVS12+2T>C in 200 normal chromosomes using SSCP
analysis revealed absence of this variant. The results of SSCP
analysis in the shifted fragment (exon 12) and DNA sequence
segment containing IVS12+2T>C are shown in Figure 2 and
Figure 3, respectively. This variant has been submitted to the
Human  PAX6  Allelic  Variant  database  (DB-ID
PAX6_00580) [6].
DISCUSSION
Aniridia is an autosomal dominant disorder resulting almost
exclusively from mutations in the PAX6 gene. It is familial in
70% cases and sporadic in others. Besides absence of iris
tissue  it  encompasses  several  ocular  abnormalities  like
glaucoma, corneal opacification, Reiger anomaly, optic nerve
defects,  CNS  abnormalities,  etc  [1,2,5].  PAX6  is  an
evolutionary  conserved  transcriptional  regulator  with
expression in the iris tissue as well as other ocular tissues
derived from neural crest cells. Its mutations are responsible
for a variety of ocular phenotypes of varying severity [5,8].
Mutations resulting in introduction of premature termination
codons (PTCs) account for 77% aniridia patients, these arising
by  nonsense  mutations,  splice  site  mutations  or  insertion/
deletions. The remaining mutations are missense or run-on
mutations  [5,9].  The  aniridia  phenotype  results  from
haploinsufficiency, which has been shown to arise in majority
of  cases  by  nonsense  mediated  decay  of  premRNA  with
premature  termination  codons  (PTCs)  [5,9].  Mutations
Figure 2. Results of SSCP analysis showing the aberrant migration
of the amplification product of the mutant exon 12 in the three
affected members (Lane 2, 3, and 4).
Figure  1.  The  family  pedigree  with
salient phenotypic features of the three
affected members.
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1307leading  to  milder  phenotypes  are  usually  missense  with
production of aberrant but functional protein [5,9].
The mutation found in the family reported here is a novel
substitution in donor splice site of Intron 12. The 10–13 exons
of PAX6 code for the PST domain, a region rich in proline,
serine  and  threonine  which  functions  as  a  transactivating
domain  that  regulates  the  PAX6  protein  homeodomain
interaction with DNA [5,8].
The RNA surveillance mechanism cannot detect PTC in
the exon13 and last 50 bp of exon 12 [5,10]. All mutations
found in this region as well as splice site mutations in intron
12  are  run-on  mutations  leading  to  haploinsufficiency  of
PAX6 by production of a protein with an elongated PST
domain that interferes with homeodomain binding to DNA.
Until date 6 variants in intron 12 have been found, 2 being non
pathogenic and 4 associated with aniridia phenotype. One of
these variants has been demonstrated to be associated with
abnormally extended 3′ end of the protein, the other three not
being characterized at the RNA level [6].
The splice site mutation found in this family is likely to
be pathogenic by leading to aberrant splicing, but its effect on
the RNA has not been established. We used the automated
splice site analysis web interface to ascertain the effect of this
mutation. The analyses predicted that the mutation would
cause decrease in binding affinity of spliceosome proteins to
this donor splice site, leading possibly to aberrant splicing
[11]. This would probably lead to abolishing of the normal
stop codon and abnormal 3′ elongation of the mRNA, which
is the most common mechanism of pathogenicity of mutations
Figure 3. Sequencing results of Exon 12 in affected individuals showing the T→C change at donor splice site of intron 12 (IVS12+2 T>C
mutation).
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1308in region distal to the 1,495th base pair of exon 12. Thus this
is likely to be a pathogenic mutation in this family.
The phenotype of this family is similar to the aniridia
cases  where  haploinsufficiency  of  PAX6  is  the  causative
mechanism. However, an interesting finding is the presence
of diffuse chorioretinal degeneration changes and vitreous
involvement in the proband in this family. Hingorani et al.
have reported the finding of Coats’ disease like exudative
vascular retinopathy in two of their patients who also had run-
on mutations leading to an elongated PST domain. These two
patients had frameshifting mutations in the exon 13 [12]. This
raises  the  possibility  that  run-on  mutations  leading  to  an
abnormal carboxy terminal extension of the PST domain may
be associated with chorioretinal involvement in patients with
aniridia.
To conclude, we report a novel splice site mutation in
PAX6  in  a  family  with  autosomal  dominant  aniridia.  The
finding of chorioretinal degeneration in association with this
probable  run-on  mutation  indicates  the  possibility  of  a
genotype-phenotype correlation.
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